1160791-70-7Relevant articles and documents
Antiplatelet activity and TNF-α release inhibition of phthalimide derivatives useful to treat sickle cell anemia
Chelucci, Rafael C.,de Oliveira, Isabela J.,Barbieri, Karina P.,Lopes-Pires, Maria E.,Polesi, Marisa C.,Chiba, Diego E.,Carlos, Iracilda Z.,Marcondes, Sisi,Dos Santos, Jean L.,Chung, ManChin
, p. 1264 - 1271 (2019/06/08)
Sickle Cell Anemia (SCA) is one of the most prevalent hereditary hematological diseases worldwide. The disease is characterized by chronic inflammation, hypercoagulable state, and pro-thrombotic profile, which lead the vaso-occlusive process. In this work
Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms
Dos Santos, Jean Leandro,Lanaro, Carolina,Lima, Ldia Moreira,Gambero, Sheley,Franco-Penteado, Carla Fernanda,Alexandre-Moreira, Magna Suzana,Wade, Marlene,Yerigenahally, Shobha,Kutlar, Abdullah,Meiler, Steffen E.,Costa, Fernando Ferreira,Chung, Manchin
experimental part, p. 5811 - 5819 (2011/10/09)
A novel series of thalidomide derivatives (4a-f) designed by molecular hybridization were synthesized and evaluated in vitro and in vivo for their potential use in the oral treatment of sickle cell disease symptoms. Compounds 4a-f demonstrated analgesic, anti-inflammatory, and NO-donor properties. Compounds 4c and 4d were considered promising candidate drugs and were further evaluated in transgenic sickle cell mice to determine their capacity to reduce the levels of the proinflammatory cytokine tumor necrosis factor α (TNFα). Unlike hydroxyurea, the compounds reduced the concentrations of TNFα to levels similar to those induced with the control dexamethasone (300 μMol/kg). These compounds are novel lead drug candidates with multiple beneficial actions in the treatment of sickle cell disease symptoms and offer an alternative to hydroxyurea treatment.
